Fluticasone propionate

Generic Name: Fluticasone propionate

Brand Names: Advair, Airduo, Airduo Respiclick, Aller-flo, Armonair, Beser, Cutivate, Dymista, Flonase, Flovent, Fluticare, Ticanase, Wixela, Xhance

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₃₁F_₃O_₅S

CAS Number: 80474-14-2

Unique Ingredient Identifier: O2GMZ0LF5W

Background: Fluticasone propionate is a synthetic glucocorticoid. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications. Fluticasone propionate was first approved in 1990.

Indication: Fluticasone propionate is indicated as an inhaler for the treatment and management of asthma by prophylaxisas well as inflammatory and pruritic dermatoses. Fluticasone propionate nasal spray is indicated for managing allergic and nonallergic rhinitis.

Associated Conditions: Allergic Rhinitis (AR), Allergy to Animal Dander, Allergy to Mold, Allergy to Tree Pollen, Asthma, Bacterial Sinusitis, Chronic Bronchitis, Chronic Obstructive Pulmonary Disease (COPD), Chronic Sinusitis, Dermatitis, Emphysema, Eosinophilic Esophagitis, House Dust Mite Allergy, House dust allergy, Itching of the nose, Nasal Congestion, Non-Allergic Rhinitis, Rhinitis, Rhinitis Perennial, Rhinorrhoea, Seasonal Allergic Rhinitis, Sneezing, Moderate, severe Perennial Allergic Rhinitis (PAR), Moderate, severe Seasonal Allergic Rhinitis

Associated Therapies: -

Clinical Trials

Should Non-eosinophilic Asthmatic Subjects be Treated With Inhaled Corticosteroids?

Not Applicable

Terminated

Conditions: Asthma

Interventions: Drug: Placebo (sham inhaler)
Drug: Fluticasone

First Posted Date: 2007-07-31

Last Posted Date: 2016-08-15

Lead Sponsor: Université de Montréal

Target Recruit Count: 12

Registration Number: NCT00509197

Locations: 🇨🇦
The Meakins-Christie Laboratories, Montreal, Quebec, Canada
🇨🇦
Calgary University, Calgary, Alberta, Canada
🇨🇦
Vancouver General Hospital, Vancouver, British Columbia, Canada

and more 4 locations

Open-label, Safety and Efficacy Study of Pulmicort® Turbuhaler® in Japanese Children With Bronchial Asthma

Phase 3

Completed

Conditions: Asthma

First Posted Date: 2007-07-19

Last Posted Date: 2011-08-24

Lead Sponsor: AstraZeneca

Target Recruit Count: 240

Registration Number: NCT00504062

Locations: 🇯🇵
Research Site, Takizawa, Iwate, Japan

Study Of RV-39 In Patients Who Also Have Asthma

Phase 4

Terminated

Conditions: Asthma

Interventions: Drug: fluticasone propionate/salmeterol
Drug: fluticasone propionate
Drug: placebo

First Posted Date: 2007-07-18

Last Posted Date: 2016-12-28

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 16

Registration Number: NCT00503009

Locations: 🇺🇸
GSK Investigational Site, Charlottesville, Virginia, United States

A Comparison of Mometasone to Advair in Patients With Milder Persistent Asthma

Phase 4

Terminated

Conditions: Asthma

Interventions: Drug: Mometasone
Drug: Advair

First Posted Date: 2007-04-18

Last Posted Date: 2017-09-20

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 33

Registration Number: NCT00461812

Locations: 🇺🇸
Johns Hopkins Asthma and Allergy Center, Baltimore, Maryland, United States

SERETIDE 100/50 bd (Twice Daily) Versus FLIXOTIDE 100 bd As Initial Maintenance Therapy In Moderate Asthma In Adults

Phase 4

Completed

Conditions: Asthma

First Posted Date: 2007-04-18

Last Posted Date: 2017-03-03

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 81

Registration Number: NCT00461500

SERETIDE Vs FLIXOTIDE In Mild Persistent Asthma (GINAII)

Phase 4

Completed

Conditions: Asthma

Interventions: Drug: Seretide
Drug: Flixotide

First Posted Date: 2007-04-04

Last Posted Date: 2018-02-05

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 100

Registration Number: NCT00455923

Locations: 🇸🇪
GSK Investigational Site, Luleå, Sweden

A 12-Week Study To Assess The Safety Of Fluticasone Propionate/Salmeterol 100/50 Hydrofluoroalkane (HFA) Versus Fluticasone Propionate 100 HFA In Children With Asthma

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: fluticasone propionate/salmeterol
Drug: fluticasone propionate

First Posted Date: 2007-03-01

Last Posted Date: 2016-12-16

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 351

Registration Number: NCT00441441

Locations: 🇪🇸
GSK Investigational Site, San Javier (Murcia), Spain

A Study of Flovent in Patients With Eosinophilic Esophagitis

Phase 2

Completed

Conditions: Eosinophilic Esophagitis

Interventions: Other: Placebo
Drug: Flovent

First Posted Date: 2007-01-24

Last Posted Date: 2020-10-19

Lead Sponsor: Marc Rothenberg, MD

Target Recruit Count: 42

Registration Number: NCT00426283

Locations: 🇺🇸
The Children's Hospital of Denver, Aurora, Colorado, United States
🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

and more 1 locations

Inhaled Fluticasone Propionate: Effect on Parameters of Bone Metabolism in Patients With Mild to Moderate Asthma

Not Applicable

Withdrawn

Conditions: Asthma

First Posted Date: 2006-12-11

Last Posted Date: 2012-04-12

Lead Sponsor: University of Kansas

Registration Number: NCT00409630

Randomized Trial of Fluticasone in Bronchial Premalignancy

Phase 2

Completed

Conditions: Bronchogenic Carcinoma

First Posted Date: 2006-12-04

Last Posted Date: 2006-12-04

Lead Sponsor: Amsterdam UMC, location VUmc

Target Recruit Count: 90

Registration Number: NCT00407264

Locations: 🇳🇱
the Netherlands Cancer Institute / Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
🇳🇱
VU medical center, Amsterdam, Netherlands

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy